Da

Prescription products · Product label record

Davimet with Iron drug information

IRON, FOLATE
PureTek Corporation · ORAL

Product NDC: 59088-160

Join the community
CommunityExperiencesReviewsDrug database
Source label information, not individualized medical advice. This record applies to the product and labeler shown below. Compare the exact formulation, strength and country with your package and the current source label.
Generic nameIRON, FOLATE
Labeler / manufacturerPureTek Corporation
RouteORAL
Drug classVitamin C / Vitamin D
Product NDC59088-160
Label effective date2024-11-27

Official product label reference

Davimet with Iron — PureTek Corporation

This page contains 11 source sections for IRON, FOLATE, oral route. Label set 1445921b-5bf4-ea48-e063-6294a90abb1a, version 3.

Retrieved 2026-10-02 · openFDA dataset updated 2026-10-02 · Check the current DailyMed label

Label records can cover multiple strengths or package sizes. A label listing does not by itself establish FDA approval or current market availability. Check the source and application history for this specific product.

Uses described in the label

INDICATIONS AND USAGE: Davimet™ with Iron Multivitamin Chewable Tablets are indicated for the treatment of iron deficiency anemia and folate deficiency, commonly seen in conditionssuch as extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. They are also indicated for condition in which irondeficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as casesof metabolic stress, and in convalescence.
Dosage and administration — label text
DOSAGE AND ADMINISTRATION: One tablet daily, to be dissolved in the mouth or chewed before swallowing.
Contraindications
CONTRAINDICATIONS: This product is contraindicated in patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients withhemosiderosis, hemochromatosis, or hemolytic anemias. Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.
Warnings
WARNING: Keep out of the reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately. Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidentaloverdose, call a doctor or poison control center immediately. Administration of folate alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B12 is deficient. CAUTION: Should be chewed. PRECAUTIONS: Folate in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive.There is a potential danger in administering folate to patients with undiagnosed anemia, since folate may obscure the diagnosis of pernicious anemia by alleviatingthe hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before thecorrect diagnosis is made. Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia. The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered. Use only under the direction of a licensed healthcare practitioner. Call your doctor about side effects. To report side effects, call PureTek Corporation at 1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Drug Interactions: Davimet™ with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with anticoagulants (e.g., Aspirin, Heparin orClopidogrel). Adverse Reactions: Folate: Allergic sensitizations have been reported following both oral and parenteral administration of folate. Iron: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy.Although the absorption of iron is best when taken between meals, giving Davimet™ with Iron Multivitamin Chewable Tablets after meals may controloccasional gastrointestinal disturbances. Davimet™ with Iron Multivitamin Chewable Tablets is best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergicand idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in somepatients
Adverse reactions
Adverse Reactions: Folate: Allergic sensitizations have been reported following both oral and parenteral administration of folate. Iron: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy.Although the absorption of iron is best when taken between meals, giving Davimet™ with Iron Multivitamin Chewable Tablets after meals may controloccasional gastrointestinal disturbances. Davimet™ with Iron Multivitamin Chewable Tablets is best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergicand idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in somepatients
Drug interactions
Drug Interactions: Davimet™ with Iron Multivitamin Chewable Tablets are not recommended and should not be given to patients receiving levodopa because the action oflevodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with anticoagulants (e.g., Aspirin, Heparin orClopidogrel).
Product description
DESCRIPTION: Each caplet contains: Vitamin A (as Retinyl Acetate).......................................750 mcg RAE Vitamin C (as Sodium Ascorbate 36 mg and Ascorbic Acid 24 mg)........ 60 mg Vitamin D3 (as Cholecalciferol)................................. 10 mcg (400 IU) Vitamin E (as DL-Alpha Tocopheryl Acetate)........................ 6.75 mg Thiamin (as Thiamine Mononitrate)....................................... 1.05 mg Riboflavin................................................................................. 1.2 mg Niacin (as Niacinamide).......................................................... 13.5 mg Vitamin B6 (as Pyridoxine Hydrochloride)............................. 1.05 mg Folate (as L-5-Methyltetrahydrofolate calcium salt)…1700 mcg DFE (1000 mcg as L-5-Methylfolate) Vitamin B12 (as Methylcobalamin)......................................... 4.5 mcg Iron (as Iron Amino Acid Chelate)............................................... 11 mg Other Ingredients: Aspartame, CI 15985 / [Yellow 6 Lake], Croscarmellose Sodium, Magnesium Stearate, Maltodextrin, Microcrystalline Cellulose, Natural OrangeFlavor, Stearic Acid (Vegetable Source), Sucrose. Phenylketonurics: Phenylalanine 3.0 mg Per Tablet.
Precautions
PRECAUTIONS: Folate in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive.There is a potential danger in administering folate to patients with undiagnosed anemia, since folate may obscure the diagnosis of pernicious anemia by alleviatingthe hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before thecorrect diagnosis is made. Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia. The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered. Use only under the direction of a licensed healthcare practitioner. Call your doctor about side effects. To report side effects, call PureTek Corporation at 1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Overdose information
OVERDOSE: Iron: Signs and Symptoms: Iron is toxic. Acute overdosage of iron may cause nausea and vomiting and, in severe cases, cardiovascular collapse and death. Othersymptoms include pallor and cyanosis, melena, shock, drowsiness and coma. The estimated overdose of orally ingested iron is 300 mg/kg body weight. Whenoverdoses are ingested by children, severe reactions, including fatalities, have resulted. Davimet™ with Iron Multivitamin Chewable Tablets should be stored beyond the reach of children to prevent against accidental iron poisoning. Treatment: For specific therapy, exchange transfusion and chelating agents should be used. For general management, perform gastric lavage with sodium bicarbonate solutionor milk. Administer intravenous fluids and electrolytes and use oxygen.
Storage and handling
Do not use if bottle seal is broken. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Supply and packaging
HOW SUPPLIED: Davimet™ with Iron Multivitamin Chewable Tablets are light orange with speckles, orange flavor, un-scored, round tablets. Available on prescription only in bottleof 30 tablets – NDC 59088-160-54. Dispense in a tight, light resistant container with a child resistant closure as defined in the USP/NF. All prescription substitutionsusing this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.

Official sources and product identifiers

Substances listed: VITAMIN A ACETATE, ASCORBIC ACID, NIACINAMIDE, PYRIDOXINE HYDROCHLORIDE, THIAMINE MONONITRATE, CHOLECALCIFEROL, IRON, RIBOFLAVIN, METHYLCOBALAMIN, SODIUM ASCORBATE, LEVOMEFOLATE CALCIUM, .ALPHA.-TOCOPHEROL ACETATE, DL-

Package NDC codes

59088-160-54

Further research and background

These are external searches for related information. Research, encyclopedia and news articles have not been imported into this product record.

Coverage and corrections

The text is extracted from a US structured product label. Tables are represented as text where supplied; formatting and illustrations may be lost. A missing section does not mean a risk is absent. This reference has not been independently reviewed by a clinician and is not a live safety-alert service.

Source retrieved 2026-10-02. Read the source policy.